Evaluation of Omarigliptin (MK-3102) in Obese Participants and in Participants With Type 2 Diabetes (MK-3102-004)
Status:
Completed
Trial end date:
2010-05-11
Target enrollment:
Participant gender:
Summary
This study will test the safety and tolerability of omarigliptin. It is hypothesized that
administration of once-weekly omarigliptin in obese but otherwise healthy participants, and
in obese participants with Type 2 diabetes (T2D) will be sufficiently safe and well tolerated
to permit continued clinical investigation.